GH Research (NASDAQ:GHRS) Shares Down 6.9% on Analyst Downgrade

GH Research PLC (NASDAQ:GHRS – Get Free Report) shares traded down 6.9% during mid-day trading on Tuesday after HC Wainwright lowered their price target on the stock from $65.00 to $55.00. HC Wainwright currently has a buy rating on the stock. GH Research traded as low as $17.97 and last traded at $17.7870. Approximately 15,632 shares traded hands during trading, a decline of 95% from the average session volume of 305,740 shares. The stock had previously closed at $19.10.

Several other brokerages also recently commented on GHRS. Needham & Company LLC increased their target price on shares of GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Zacks Research raised shares of GH Research from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Wall Street Zen upgraded shares of GH Research from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. Finally, Wells Fargo & Company started coverage on shares of GH Research in a research report on Monday, July 27th. They issued an “overweight” rating and a $44.00 price objective for the company. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, GH Research presently has an average rating of “Moderate Buy” and a consensus price target of $44.00.

Read Our Latest Stock Analysis on GH Research

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of GHRS. Royal Bank of Canada grew its stake in GH Research by 43.1% in the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after purchasing an additional 780 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of GH Research during the 3rd quarter valued at $82,000. Bellevue Group AG bought a new stake in shares of GH Research during the 3rd quarter worth $109,000. Farther Finance Advisors LLC raised its stake in shares of GH Research by 9,720.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock worth $231,000 after purchasing an additional 9,720 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of GH Research by 30.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,525 shares of the company’s stock worth $432,000 after purchasing an additional 4,106 shares during the period. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Trading Down 0.1%

The stock’s fifty day moving average is $21.73 and its two-hundred day moving average is $21.68. The company has a market capitalization of $1.25 billion, a PE ratio of -19.21 and a beta of 1.31.

GH Research (NASDAQ:GHRS – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.13. As a group, analysts anticipate that GH Research PLC will post -1.20 EPS for the current fiscal year.

About GH Research

(Get Free Report)

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.

Further Reading

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.